Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1

This study is ongoing, but not recruiting participants.

First Received: June 18, 2002 Last Updated: February 8, 2007 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	University of California, Los Angeles
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00040040

Purpose

The purpose of this study is to assess potential interactions between intravenous (IV) methamphetamine and oral bupropion.

Condition	Intervention	Phase
Amphetamine-Related Disorders	Drug: Bupropion	Phase I

Study Type:	Interventional
Study Design:	Diagnostic, Randomized, Double-Blind, Placebo Control
Official Title:	Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between IV Methamphetamine and Oral Bupropion

Resource links provided by NLM:

MedlinePlus related topics: Methamphetamine

Drug Information available for: Methamphetamine hydrochloride Bupropion hydrochloride Bupropion Amphetamine Methamphetamine

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Psychological effects
BP, HR

Estimated Enrollment:	20
Study Start Date:	June 2002
Estimated Study Completion Date:	September 2003

Detailed Description:

This is a human laboratory clinical pharmacology study to assess potential interactions between IV methamphetamine challenge and treatment with oral sustained-release bupropion.

Eligibility

Ages Eligible for Study:	18 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Please contact site director for more details.

Exclusion Criteria:

Please contact site director for more details.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00040040

Locations

United States, California
UCLA Integrated Substance Abuse Program
Los Angeles, California, United States, 90024
United States, Texas
University of Texas Health Science Center
Houston, Texas, United States, 77225

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of California, Los Angeles

Investigators

Principal Investigator:

Thomas Newton, M.D.

National Institute on Drug Abuse (NIDA)

More Information

No publications provided

Study ID Numbers:	NIDA-CTO-0010-1
Study First Received:	June 18, 2002
Last Updated:	February 8, 2007
ClinicalTrials.gov Identifier:	NCT00040040 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Physiological Effects of Drugs
Psychotropic Drugs
Disorders of Environmental Origin
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Antidepressive Agents, Second-Generation

Antidepressive Agents
Sympathomimetics
Central Nervous System Stimulants
Pharmacologic Actions
Methamphetamine
Autonomic Agents
Amphetamine-Related Disorders
Bupropion
Dopamine Agents
Amphetamine
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 27, 2009